JP2017512063A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512063A5
JP2017512063A5 JP2016555527A JP2016555527A JP2017512063A5 JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5 JP 2016555527 A JP2016555527 A JP 2016555527A JP 2016555527 A JP2016555527 A JP 2016555527A JP 2017512063 A5 JP2017512063 A5 JP 2017512063A5
Authority
JP
Japan
Prior art keywords
fusion protein
residue
multimeric fusion
region
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555527A
Other languages
English (en)
Japanese (ja)
Other versions
JP6851200B2 (ja
JP2017512063A (ja
Filing date
Publication date
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/054687 external-priority patent/WO2015132364A1/en
Publication of JP2017512063A publication Critical patent/JP2017512063A/ja
Publication of JP2017512063A5 publication Critical patent/JP2017512063A5/ja
Application granted granted Critical
Publication of JP6851200B2 publication Critical patent/JP6851200B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555527A 2014-03-05 2015-03-05 多量体Fcタンパク質 Expired - Fee Related JP6851200B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403913.5 2014-03-05
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB1403912.7 2014-03-05
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB1405952.1 2014-04-02
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
GB1412646.0 2014-07-16
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (3)

Publication Number Publication Date
JP2017512063A JP2017512063A (ja) 2017-05-18
JP2017512063A5 true JP2017512063A5 (enExample) 2018-04-12
JP6851200B2 JP6851200B2 (ja) 2021-03-31

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016555527A Expired - Fee Related JP6851200B2 (ja) 2014-03-05 2015-03-05 多量体Fcタンパク質

Country Status (15)

Country Link
US (1) US11352414B2 (enExample)
EP (1) EP3114143B1 (enExample)
JP (1) JP6851200B2 (enExample)
KR (1) KR20160130463A (enExample)
CN (1) CN106068274A (enExample)
AU (1) AU2015226100B2 (enExample)
BR (1) BR112016020368A2 (enExample)
CA (1) CA2939198A1 (enExample)
IL (1) IL247096A0 (enExample)
MX (1) MX2016010951A (enExample)
RU (1) RU2016139006A (enExample)
SG (1) SG11201606597QA (enExample)
TW (1) TW201619188A (enExample)
UY (1) UY36021A (enExample)
WO (1) WO2015132364A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3114143B1 (en) * 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
JP2017518965A (ja) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたFc構築物に関連する組成物および方法
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
BR112018014668A2 (pt) * 2016-01-27 2018-12-11 Csl Behring Recombinant Facility Ag multímeros de fc de igg recombinante
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
DK3484514T3 (da) 2016-05-23 2024-01-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
CN109641048A (zh) 2016-07-22 2019-04-16 格利克尼克股份有限公司 产生具有增强的Fc受体结合的经有序多聚化的免疫球蛋白Fc组合物的人蛋白片段的融合蛋白
MX2019006573A (es) 2016-12-09 2019-11-18 Gliknik Inc Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
SG11201906139VA (en) 2017-01-06 2019-08-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
JP7395463B2 (ja) * 2017-03-28 2023-12-11 リビジェン バイオファーマ ホールディングス リミテッド 腫瘍微小環境における免疫応答を増強するための治療剤および方法
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
AU2018281045A1 (en) * 2017-06-05 2019-12-12 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
ES2975776T3 (es) * 2017-12-14 2024-07-15 CSL Behring Lengnau AG Multímeros de Fc de IgG recombinantes para el tratamiento de la neuromielitis óptica
WO2019175605A1 (en) * 2018-03-16 2019-09-19 Liverpool School Of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
EP3880248A4 (en) * 2018-11-14 2022-08-10 JN Biosciences, LLC MULTIMERIC HYBRID FC PROTEINS FOR IV IG REPLACEMENT
US20220332847A1 (en) 2019-09-13 2022-10-20 CSL Behring Lengnau AG RECOMBINANT IgG Fc MULTIMERS FOR THE TREATMENT OF IMMUNE COMPLEX-MEDIATED KIDNEY DISORDERS
CA3159705A1 (en) * 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业(上海)股份有限公司 一种cdc平台抗体
CN119546338A (zh) * 2022-06-10 2025-02-28 研究发展基金会 经改造FcRIIB选择性IgG1 Fc变体及其用途

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Fc 변이체
EP3805269A1 (en) 2006-06-12 2021-04-14 Aptevo Research and Development LLC Single-chain multivalent binding proteins with effector function
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN103897063B (zh) * 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2389192A4 (en) 2009-01-23 2013-01-16 Biogen Idec Inc STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE
CN102781963B (zh) 2009-10-27 2018-02-16 Ucb医药有限公司 功能修饰性NAv1.7抗体
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
CA2902942C (en) 2010-07-28 2020-12-22 David S. Block Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CN103974977A (zh) 2011-09-26 2014-08-06 Jn生物科学有限责任公司 杂交恒定区
SG11201403444UA (en) 2011-12-21 2014-07-30 Amgen Inc Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
EP2869845B1 (en) 2012-07-06 2019-08-28 Genmab B.V. Dimeric protein with triple mutations
MX2015000683A (es) 2012-08-02 2015-04-10 Hoffmann La Roche Metodo para producir moleculas monomericas y multimericas y uso de las mismas.
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
RU2015109591A (ru) 2012-08-20 2016-10-20 Гликник Инк. Молекулы с антигенсвязывающей активностью и способностью к поливалентному связыванию с fc-гамма-рецепторами
BR112015008663B1 (pt) 2012-10-17 2021-01-12 CSL Behring Lengnau AG Uso de uma quantidade eficaz de uma proteína polimérica compreendendo seis unidades demonômero de polipeptídeo
EP3114143B1 (en) 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
AU2015226101B2 (en) 2014-03-05 2019-08-22 Ucb Biopharma Sprl Multimeric Fc proteins
BR112016023948A2 (pt) 2014-04-16 2018-01-30 Ucb Biopharma Sprl proteínas fc multiméricas
JP2017518965A (ja) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたFc構築物に関連する組成物および方法
CA2978501A1 (en) 2015-03-05 2016-09-09 Ucb Biopharma Sprl Polymeric fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Similar Documents

Publication Publication Date Title
JP2017512063A5 (enExample)
JP2017509335A5 (enExample)
RU2010122053A (ru) Иммуносупрессорные полипептиды и нуклеиновые кислоты
CN103596968B (zh) 用于亲和层析的洗涤溶液和方法
JP2016526909A5 (enExample)
HRP20220080T1 (hr) Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin
JP2019522465A5 (enExample)
RU2016139006A (ru) Мультимерные fc-белки
NZ606427A (en) Extended recombinant polypeptides and compositions comprising same
RU2016139022A (ru) МУЛЬТИМЕРНЫЕ Fc-БЕЛКИ
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
HRP20220960T1 (hr) Kimerni proteini faktora viii i njihova upotreba
JP2016525100A5 (enExample)
RU2013140685A (ru) ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
MX2009012319A (es) Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
JP2020500015A5 (enExample)
JP2019516665A5 (enExample)
JP2014506790A5 (enExample)
JP2005120106A5 (enExample)
RU2018138703A (ru) Слитые полипептиды cd40l-fc и способы их применения
HRP20231496T1 (hr) Cistein proteaza
IL276286B1 (en) FC variants with improved binding to FCRN and extended half-life
JP2016523959A5 (enExample)
JP2018514209A5 (enExample)